25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Herantis Pharma Oyj
Buy, Hold or Sell?

Let's analyze Herantis together

I guess you are interested in Herantis Pharma Oyj. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Herantis Pharma Oyj. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Herantis Pharma Oyj

I send you an email if I find something interesting about Herantis Pharma Oyj.

Quick analysis of Herantis (30 sec.)










What can you expect buying and holding a share of Herantis? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
‚ā¨0.23
Expected worth in 1 year
‚ā¨2.37
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨2.13
Return On Investment
137.2%

For what price can you sell your share?

Current Price per Share
‚ā¨1.56
Expected price per share
‚ā¨1.45 - ‚ā¨1.745
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Herantis (5 min.)




Live pricePrice per Share (EOD)

‚ā¨1.56

Intrinsic Value Per Share

‚ā¨-111.27 - ‚ā¨-37.06

Total Value Per Share

‚ā¨-111.03 - ‚ā¨-36.82

2. Growth of Herantis (5 min.)




Is Herantis growing?

Current yearPrevious yearGrowGrow %
How rich?$5.1m-$6.5m$11.6m227.5%

How much money is Herantis making?

Current yearPrevious yearGrowGrow %
Making money$303.4k-$11.5m$11.8m3,908.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Herantis (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#712 / 982

Most Revenue
#943 / 982

Most Profit
#147 / 982

Most Efficient
#214 / 982
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Herantis? (5 min.)

Welcome investor! Herantis's management wants to use your money to grow the business. In return you get a share of Herantis.

What can you expect buying and holding a share of Herantis?

First you should know what it really means to hold a share of Herantis. And how you can make/lose money.

Speculation

The Price per Share of Herantis is ‚ā¨1.555. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Herantis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Herantis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨0.23. Based on the TTM, the Book Value Change Per Share is ‚ā¨0.53 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Herantis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps0.021.0%0.021.0%-0.50-32.3%-0.42-27.0%-0.40-25.6%
Usd Book Value Change Per Share0.5837.2%0.5837.2%-0.26-16.9%0.053.3%0.021.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.5837.2%0.5837.2%-0.26-16.9%0.053.3%0.021.6%
Usd Price Per Share1.71-1.71-1.79-3.80-4.26-
Price to Earnings Ratio113.47-113.47--3.57-15.49--3.02-
Price-to-Total Gains Ratio2.95-2.95--6.81-17.14-9.43-
Price to Book Ratio6.72-6.72--5.52-10.84--111.46-
Price-to-Total Gains Ratio2.95-2.95--6.81-17.14-9.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.686242
Number of shares593
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.580.05
Usd Total Gains Per Share0.580.05
Gains per Quarter (593 shares)343.0330.72
Gains per Year (593 shares)1,372.11122.88
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10137213620123113
20274427340246236
30411641060369359
40548854780492482
50686168500614605
60823382220737728
70960595940860851
8010977109660983974
901234912338011061097
1001372113710012291220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%1.09.00.010.0%1.011.00.08.3%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%6.06.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.012.00.0%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%6.06.00.050.0%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Herantis

About Herantis Pharma Oyj

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.

Fundamental data was last updated by Penke on 2024-07-20 07:49:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Herantis Pharma Oyj.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Herantis earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Herantis to the¬†Biotechnology industry mean.
  • A Net Profit Margin of 0.0%¬†means that¬†€0.00 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Herantis Pharma Oyj:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-188,274.9%+188,274.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.6%+168.6%
TTM--209.9%+209.9%
YOY--235.1%+235.1%
5Y--390.8%+390.8%
10Y-188,274.9%-505.1%-187,769.8%
1.1.2. Return on Assets

Shows how efficient Herantis is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Herantis to the¬†Biotechnology industry mean.
  • 4.1% Return on Assets means that¬†Herantis generated¬†€0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Herantis Pharma Oyj:

  • The MRQ is 4.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.1%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.1%TTM4.1%0.0%
TTM4.1%YOY-1.7%+5.9%
TTM4.1%5Y-61.7%+65.8%
5Y-61.7%10Y-57.1%-4.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1%-11.7%+15.8%
TTM4.1%-11.8%+15.9%
YOY-1.7%-11.2%+9.5%
5Y-61.7%-13.2%-48.5%
10Y-57.1%-14.6%-42.5%
1.1.3. Return on Equity

Shows how efficient Herantis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Herantis to the¬†Biotechnology industry mean.
  • 5.9% Return on Equity means Herantis generated €0.06¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Herantis Pharma Oyj:

  • The MRQ is 5.9%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.9%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.9%TTM5.9%0.0%
TTM5.9%YOY-+5.9%
TTM5.9%5Y-121.7%+127.6%
5Y-121.7%10Y-124.8%+3.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.9%-14.0%+19.9%
TTM5.9%-15.2%+21.1%
YOY--14.0%+14.0%
5Y-121.7%-18.8%-102.9%
10Y-124.8%-19.3%-105.5%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Herantis Pharma Oyj.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Herantis is operating .

  • Measures how much profit Herantis makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Herantis to the¬†Biotechnology industry mean.
  • An Operating Margin of 0.0%¬†means the company generated €0.00 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Herantis Pharma Oyj:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-176,227.0%+176,227.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--351.1%+351.1%
TTM--224.3%+224.3%
YOY--243.1%+243.1%
5Y--396.3%+396.3%
10Y-176,227.0%-510.1%-175,716.9%
1.2.2. Operating Ratio

Measures how efficient Herantis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y1,801.775-1,801.775
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM-3.255-3.255
YOY-3.484-3.484
5Y-5.004-5.004
10Y1,801.7756.533+1,795.242
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Herantis Pharma Oyj.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Herantis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 3.39¬†means the company has €3.39 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 3.391. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.391. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.391TTM3.3910.000
TTM3.391YOY3.277+0.113
TTM3.3915Y3.573-0.182
5Y3.57310Y4.561-0.988
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3913.793-0.402
TTM3.3914.052-0.661
YOY3.2774.945-1.668
5Y3.5735.990-2.417
10Y4.5616.326-1.765
1.3.2. Quick Ratio

Measures if Herantis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Herantis to the¬†Biotechnology industry mean.
  • A Quick Ratio of 0.50¬†means the company can pay off €0.50 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 0.495. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.495. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.495TTM0.4950.000
TTM0.495YOY3.653-3.158
TTM0.4955Y3.301-2.806
5Y3.30110Y6.689-3.388
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4953.186-2.691
TTM0.4953.581-3.086
YOY3.6534.803-1.150
5Y3.3015.922-2.621
10Y6.6896.430+0.259
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Herantis Pharma Oyj.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Herantis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Herantis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30¬†means that Herantis assets are¬†financed with 29.9% credit (debt) and the remaining percentage (100% - 29.9%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 0.299. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.299. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.299TTM0.2990.000
TTM0.299YOY1.010-0.710
TTM0.2995Y0.765-0.466
5Y0.76510Y0.717+0.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2990.330-0.031
TTM0.2990.340-0.041
YOY1.0100.287+0.723
5Y0.7650.368+0.397
10Y0.7170.383+0.334
1.4.2. Debt to Equity Ratio

Measures if Herantis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Herantis to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 42.7% means that company has €0.43 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 0.427. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.427. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.427TTM0.4270.000
TTM0.427YOY-+0.427
TTM0.4275Y1.314-0.887
5Y1.31410Y1.559-0.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4270.366+0.061
TTM0.4270.415+0.012
YOY-0.369-0.369
5Y1.3140.441+0.873
10Y1.5590.483+1.076
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Herantis Pharma Oyj

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Herantis generates.

  • Above 15 is considered overpriced but¬†always compare¬†Herantis to the¬†Biotechnology industry mean.
  • A PE ratio of 113.47 means the investor is paying €113.47¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Herantis Pharma Oyj:

  • The EOD is 112.028. Based on the earnings, the company is expensive. -2
  • The MRQ is 113.469. Based on the earnings, the company is expensive. -2
  • The TTM is 113.469. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD112.028MRQ113.469-1.441
MRQ113.469TTM113.4690.000
TTM113.469YOY-3.568+117.037
TTM113.4695Y15.490+97.979
5Y15.49010Y-3.020+18.511
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD112.028-2.610+114.638
MRQ113.469-3.020+116.489
TTM113.469-2.891+116.360
YOY-3.568-3.549-0.019
5Y15.490-6.222+21.712
10Y-3.020-6.322+3.302
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Herantis Pharma Oyj:

  • The EOD is -6.762. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.849. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.849. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.762MRQ-6.849+0.087
MRQ-6.849TTM-6.8490.000
TTM-6.849YOY-0.037-6.812
TTM-6.8495Y-9.551+2.702
5Y-9.55110Y-17.295+7.745
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.762-3.139-3.623
MRQ-6.849-3.748-3.101
TTM-6.849-3.717-3.132
YOY-0.037-5.038+5.001
5Y-9.551-7.998-1.553
10Y-17.295-8.522-8.773
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Herantis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of 6.72 means the investor is paying €6.72¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Herantis Pharma Oyj:

  • The EOD is 6.633. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.718. Based on the equity, the company is overpriced. -1
  • The TTM is 6.718. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.633MRQ6.718-0.085
MRQ6.718TTM6.7180.000
TTM6.718YOY-5.518+12.237
TTM6.7185Y10.841-4.122
5Y10.84110Y-111.458+122.299
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.6331.928+4.705
MRQ6.7182.247+4.471
TTM6.7182.301+4.417
YOY-5.5182.387-7.905
5Y10.8413.674+7.167
10Y-111.4584.139-115.597
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Herantis Pharma Oyj compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5330.5330%-0.242+145%0.048+1017%0.023+2235%
Book Value Per Share--0.2340.2340%-0.299+228%0.069+238%0.200+17%
Current Ratio--3.3913.3910%3.277+3%3.573-5%4.561-26%
Debt To Asset Ratio--0.2990.2990%1.010-70%0.765-61%0.717-58%
Debt To Equity Ratio--0.4270.4270%-+100%1.314-67%1.559-73%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0140.0140%-0.462+3432%-0.387+2885%-0.368+2749%
Free Cash Flow Per Share---0.230-0.2300%-44.363+19192%-9.161+3884%-4.685+1938%
Free Cash Flow To Equity Per Share---0.230-0.2300%-1.907+729%-0.375+63%-0.177-23%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---37.058--------
Intrinsic Value_10Y_min---111.266--------
Intrinsic Value_1Y_max---4.486--------
Intrinsic Value_1Y_min---14.195--------
Intrinsic Value_3Y_max---12.890--------
Intrinsic Value_3Y_min---40.264--------
Intrinsic Value_5Y_max---20.584--------
Intrinsic Value_5Y_min---63.521--------
Market Cap31349888.500-1%31753154.47531753154.4750%33265155.000-5%70663263.895-55%79140833.048-60%
Net Profit Margin----0%-0%-0%-1882.7490%
Operating Margin----0%-0%-0%-1762.2700%
Operating Ratio----0%-0%-0%1801.775-100%
Pb Ratio6.633-1%6.7186.7180%-5.518+182%10.841-38%-111.458+1759%
Pe Ratio112.028-1%113.469113.4690%-3.568+103%15.490+633%-3.020+103%
Price Per Share1.555-1%1.5751.5750%1.650-5%3.505-55%3.926-60%
Price To Free Cash Flow Ratio-6.762+1%-6.849-6.8490%-0.037-99%-9.551+39%-17.295+153%
Price To Total Gains Ratio2.915-1%2.9532.9530%-6.806+331%17.143-83%9.435-69%
Quick Ratio--0.4950.4950%3.653-86%3.301-85%6.689-93%
Return On Assets--0.0410.0410%-0.017+141%-0.617+1587%-0.571+1477%
Return On Equity--0.0590.0590%-+100%-1.217+2155%-1.248+2208%
Total Gains Per Share--0.5330.5330%-0.242+145%0.048+1017%0.023+2235%
Usd Book Value--5125257.9415125257.9410%-6536907.425+228%1517362.205+238%4369338.264+17%
Usd Book Value Change Per Share--0.5780.5780%-0.263+145%0.052+1017%0.025+2235%
Usd Book Value Per Share--0.2540.2540%-0.324+228%0.075+238%0.217+17%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0150.0150%-0.502+3432%-0.419+2885%-0.399+2749%
Usd Free Cash Flow---5027285.232-5027285.2320%-969877832.462+19192%-200284285.378+3884%-102434795.458+1938%
Usd Free Cash Flow Per Share---0.249-0.2490%-48.107+19192%-9.934+3884%-5.081+1938%
Usd Free Cash Flow To Equity Per Share---0.249-0.2490%-2.068+729%-0.407+63%-0.192-23%
Usd Market Cap33995819.089-1%34433120.71334433120.7130%36072734.082-5%76627243.368-55%85820319.357-60%
Usd Price Per Share1.686-1%1.7081.7080%1.789-5%3.801-55%4.257-60%
Usd Profit--303457.520303457.5200%-11556134.947+3908%-9230619.975+3142%-8429125.076+2878%
Usd Revenue----0%-0%-0%3041.407-100%
Usd Total Gains Per Share--0.5780.5780%-0.263+145%0.052+1017%0.025+2235%
 EOD+3 -5MRQTTM+0 -0YOY+22 -75Y+21 -810Y+19 -12

3.2. Fundamental Score

Let's check the fundamental score of Herantis Pharma Oyj based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15112.028
Price to Book Ratio (EOD)Between0-16.633
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.495
Current Ratio (MRQ)Greater than13.391
Debt to Asset Ratio (MRQ)Less than10.299
Debt to Equity Ratio (MRQ)Less than10.427
Return on Equity (MRQ)Greater than0.150.059
Return on Assets (MRQ)Greater than0.050.041
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Herantis Pharma Oyj based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.220
Ma 20Greater thanMa 501.551
Ma 50Greater thanMa 1001.578
Ma 100Greater thanMa 2001.496
OpenGreater thanClose1.530
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Income before Tax  -8,005-1,148-9,153-3,614-12,7673,443-9,3249,604280
Net Income  -8,873-1,362-10,235-2,840-13,0752,419-10,65710,937280
Operating Income  -7,155-917-8,072-4,389-12,4614,469-7,9928,146154
Net Interest Income  -849-232-1,081775-306-1,025-1,3311,457125
Total Operating Expenses  7,1559178,0724,38912,461-7,1715,290-5,444-154
Net Income from Continuing Operations  -8,005-1,148-9,153-3,614-12,7673,443-9,3249,604280



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets6,746
Total Liabilities2,019
Total Stockholder Equity4,726
 As reported
Total Liabilities 2,019
Total Stockholder Equity+ 4,726
Total Assets = 6,746

Assets

Total Assets6,746
Total Current Assets6,746
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 5,503
Short-term Investments 985
Total Current Assets  (as reported)6,746
Total Current Assets  (calculated)6,488
+/- 257
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,989
Long-term Liabilities30
Total Stockholder Equity4,726
Total Current Liabilities
Short Long Term Debt 5
Accounts payable 749
Total Current Liabilities  (as reported)1,989
Total Current Liabilities  (calculated)754
+/- 1,236
Long-term Liabilities
Long term Debt 30
Long-term Liabilities  (as reported)30
Long-term Liabilities  (calculated)30
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)4,726
Total Stockholder Equity (calculated)0
+/- 4,726
Other
Capital Stock80
Common Stock Shares Outstanding 20,161
Net Invested Capital 4,761
Net Working Capital 4,756



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
> Total Assets 
670
2,211
2,641
29,495
14,089
10,205
11,573
7,148
11,071
16,420
7,762
623,214
6,746
6,746623,2147,76216,42011,0717,14811,57310,20514,08929,4952,6412,211670
   > Total Current Assets 
346
153
43
11,638
5,646
2,895
5,511
2,290
7,260
13,541
7,602
623,214
6,746
6,746623,2147,60213,5417,2602,2905,5112,8955,64611,63843153346
       Cash And Cash Equivalents 
246
9
18
2,416
541
782
91
719
6,013
12,339
6,439
503,580
5,503
5,503503,5806,43912,3396,013719917825412,416189246
       Short-term Investments 
0
0
0
9,000
5,000
2,047
5,311
1,466
985
985
985
95,505
985
98595,5059859859851,4665,3112,0475,0009,000000
       Net Receivables 
57
144
25
213
87
42
91
94
245
174
118
0
0
00118174245949142872132514457
   > Long-term Assets 
324
2,058
2,598
17,857
8,442
7,311
6,061
4,857
3,811
2,879
160
0
0
001602,8793,8114,8576,0617,3118,44217,8572,5982,058324
       Property Plant Equipment 
4
3
2
2
1
9
7
5
4
0
0
0
0
0000457912234
       Goodwill 
0
0
0
905
696
544
311
78
0
0
0
0
0
0000078311544696905000
       Long Term Investments 
0
0
0
1
1
1
1
0
0
0
0
0
0
0000001111000
       Intangible Assets 
320
2,055
240
16,950
7,744
6,757
5,743
4,775
3,807
2,879
160
0
0
001602,8793,8074,7755,7436,7577,74416,9502402,055320
       Other Assets 
0
1,775
2,356
16,670
7,518
6,590
5,663
0
3,807
2,879
160
0
0
001602,8793,80705,6636,5907,51816,6702,3561,7750
> Total Liabilities 
1,920
2,215
2,521
7,774
8,089
8,631
7,482
7,237
9,220
8,833
8,902
629,242
2,019
2,019629,2428,9028,8339,2207,2377,4828,6318,0897,7742,5212,2151,920
   > Total Current Liabilities 
672
536
670
1,494
578
613
1,460
1,358
2,014
2,892
2,614
190,153
1,989
1,989190,1532,6142,8922,0141,3581,4606135781,494670536672
       Short-term Debt 
0
0
1,850
240
213
103
547
507
6
1,265
912
15,021
0
015,0219121,26565075471032132401,85000
       Short Long Term Debt 
0
0
1,850
240
213
103
547
507
6
1,265
912
15,021
5
515,0219121,26565075471032132401,85000
       Accounts payable 
618
468
544
988
189
186
278
200
1,625
716
789
66,030
749
74966,0307897161,625200278186189988544468618
       Other Current Liabilities 
55
67
127
267
176
324
634
651
383
911
913
109,101
0
0109,1019139113836516343241762671276755
   > Long-term Liabilities 
1,248
1,679
1,850
6,280
7,512
8,018
6,022
5,878
7,206
5,941
6,288
439,089
30
30439,0896,2885,9417,2065,8786,0228,0187,5126,2801,8501,6791,248
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
5,941
6,288
4,391
0
04,3916,2885,941000000000
       Long term Debt 
1,248
1,679
1,850
6,280
7,512
8,018
6,022
5,878
7,206
5,941
6,288
4,391
30
304,3916,2885,9417,2065,8786,0228,0187,5126,2801,8501,6791,248
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000
       Deferred Long Term Liability 
0
0
2,356
16,670
7,518
6,590
5,663
4,735
3,807
2,879
160
0
0
001602,8793,8074,7355,6636,5907,51816,6702,35600
> Total Stockholder Equity
-1,250
-3
120
21,721
5,999
1,575
4,090
-89
1,851
7,587
-1,140
-6,028
4,726
4,726-6,028-1,1407,5871,851-894,0901,5755,99921,721120-3-1,250
   Common Stock
3
3
3
80
80
80
80
80
80
80
80
8,000
0
08,0008080808080808080333
   Retained Earnings -75,100-7,537,970-67,750-54,983-45,830-37,825-33,646-31,481-27,057-11,012-3,427-2,646-2,252
   Capital Surplus 0000000000000
   Treasury Stock0000000000000
   Other Stockholders Equity 
1,000
2,640
3,544
32,653
32,976
32,976
37,656
37,656
47,601
62,490
66,530
7,523,942
0
07,523,94266,53062,49047,60137,65637,65632,97632,97632,6533,5442,6401,000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense--154
Operating Income154154
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense-1540
 
Net Interest Income (+$)
Interest Income37
Interest Expense-21
Other Finance Cost-110
Net Interest Income125
 
Pretax Income (+$)
Operating Income154
Net Interest Income125
Other Non-Operating Income Expenses0
Income Before Tax (EBT)280154
EBIT - interestExpense = -21
280
301
Interest Expense21
Earnings Before Interest and Taxes (EBIT)0301
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax280
Tax Provision-0
Net Income From Continuing Ops280280
Net Income280
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-125
 

Technical Analysis of Herantis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Herantis. The general trend of Herantis is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Herantis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Herantis Pharma Oyj.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.56 < 1.585 < 1.745.

The bearish price targets are: 1.5 > 1.45 > 1.45.

Tweet this
Herantis Pharma Oyj Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging¬†trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Herantis Pharma Oyj. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Herantis Pharma Oyj Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a¬†lagging momentum¬†indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Herantis Pharma Oyj. The current macd is -0.02362443.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Herantis price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Herantis. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Herantis price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Herantis Pharma Oyj Daily Moving Average Convergence/Divergence (MACD) ChartHerantis Pharma Oyj Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Herantis Pharma Oyj. The current adx is 18.11.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Herantis shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Herantis Pharma Oyj Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows¬†the current trend.
  • Shows¬†potential entry signals.
  • Shows¬†¬†potential exit signals.
  • Can be used to place¬†trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Herantis Pharma Oyj. The current sar is 1.59964634.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Herantis Pharma Oyj Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum¬†indicator, meaning the signals are instant.
  • Ranges¬†between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Herantis Pharma Oyj. The current rsi is 50.22. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Herantis Pharma Oyj Daily Relative Strength Index (RSI) ChartHerantis Pharma Oyj Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading¬†momentum¬†indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges¬†between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Herantis Pharma Oyj. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Herantis price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Herantis Pharma Oyj Daily Stochastic Oscillator ChartHerantis Pharma Oyj Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,¬†the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Herantis Pharma Oyj. The current cci is -7.85193494.

Herantis Pharma Oyj Daily Commodity Channel Index (CCI) ChartHerantis Pharma Oyj Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Herantis Pharma Oyj. The current cmo is 5.17850149.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Herantis Pharma Oyj Daily Chande Momentum Oscillator (CMO) ChartHerantis Pharma Oyj Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and¬†-100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Herantis Pharma Oyj. The current willr is -19.23076923.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Herantis Pharma Oyj Daily Williams %R ChartHerantis Pharma Oyj Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold¬†

Score

Let's take a look at the Bollinger Bands of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Herantis Pharma Oyj. The current atr is 0.07623374.

Herantis Pharma Oyj Daily Average True Range (ATR) ChartHerantis Pharma Oyj Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Herantis Pharma Oyj. The current obv is 64,240.

Herantis Pharma Oyj Daily On-Balance Volume (OBV) ChartHerantis Pharma Oyj Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Herantis Pharma Oyj. The current mfi is 29.23.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Herantis Pharma Oyj Daily Money Flow Index (MFI) ChartHerantis Pharma Oyj Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Herantis Pharma Oyj.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-24BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-05-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-31WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Herantis Pharma Oyj Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Herantis Pharma Oyj based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.220
Ma 20Greater thanMa 501.551
Ma 50Greater thanMa 1001.578
Ma 100Greater thanMa 2001.496
OpenGreater thanClose1.530
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0